Clinical data continues to demonstrate that tumours which are more visible to the immune system show improved responses to checkpoint inhibitors. Grey Wolf has developed unique insight into the targeting of the ERAP enzymes and validated the role for ERAP inhibition in modulating the cancer-related antigen repertoire. These in-house data provide compelling evidence that the therapies could have a real impact in the treatment of oncology. Grey Wolf combines first class drug discovery, in depth investigative biology, with biomarker discovery and development to guide clinical development.

DiscoveryPreclinicalPhase 1 Safety Dose-Escalation Phase 1b Dose-Expansion/Efficacy Signal
ERAP1
  • Preclinical
ERAP2
  • Discovery